Medicus Pharma Ltd. Common Stock
Medicus Pharma Ltd., a biotech/life sciences company, focuses on developing clinical development programs of therapeutic assets in the United States. It is developing SKNJCT-003, which is in Phase 2 study for the treatment of basal cell carcinoma of the skin. Medicus Pharma Ltd. has a strategic collaboration with the Gorlin Syndrome Alliance to access to SKINJECT in Patients with Gorlin Syndrome.… Read more
Medicus Pharma Ltd. Common Stock (MDCX) - Total Liabilities
Latest total liabilities as of September 2025: $10.78 Million USD
Based on the latest financial reports, Medicus Pharma Ltd. Common Stock (MDCX) has total liabilities worth $10.78 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Medicus Pharma Ltd. Common Stock - Total Liabilities Trend (2010–2024)
This chart illustrates how Medicus Pharma Ltd. Common Stock's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Medicus Pharma Ltd. Common Stock Competitors by Total Liabilities
The table below lists competitors of Medicus Pharma Ltd. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Mercer Bancorp Inc.
OTCGREY:MSBB
|
USA | $152.89 Million |
|
JG Environmental Technology Co.,Ltd.
TWO:6723
|
Taiwan | NT$350.54 Million |
|
Electromagnetica SA
RO:ELMA
|
Romania | RON41.97 Million |
|
Kronox Lab Sciences Ltd
NSE:KRONOX
|
India | ₹112.75 Million |
|
CryoCell International Inc
NYSE MKT:CCEL
|
USA | $78.00 Million |
|
The INX Digital Company Inc.
OTCQB:INXDF
|
USA | $48.72 Million |
|
Galena Mining Ltd
AU:G1A
|
Australia | AU$264.35 Million |
|
Traws Pharma Inc
NASDAQ:TRAW
|
USA | $7.90 Million |
Liability Composition Analysis (2010–2024)
This chart breaks down Medicus Pharma Ltd. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.92 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -11.85 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.08 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Medicus Pharma Ltd. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Medicus Pharma Ltd. Common Stock (2010–2024)
The table below shows the annual total liabilities of Medicus Pharma Ltd. Common Stock from 2010 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $2.51 Million | +221.41% |
| 2023-12-31 | $781.61K | -93.74% |
| 2022-12-31 | $12.48 Million | +17.92% |
| 2021-12-31 | $10.58 Million | +10152.60% |
| 2017-12-31 | $103.23K | +1024.19% |
| 2016-12-31 | $9.18K | +168.82% |
| 2015-12-31 | $3.42K | -99.93% |
| 2010-12-31 | $5.00 Million | -- |